Bellevue Group AG Sells 279,454 Shares of Moderna, Inc. $MRNA

Bellevue Group AG lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 18.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,238,668 shares of the company’s stock after selling 279,454 shares during the period. Bellevue Group AG’s holdings in Moderna were worth $34,175,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MRNA. Norges Bank bought a new stake in Moderna in the 2nd quarter worth about $94,910,000. Federated Hermes Inc. lifted its position in shares of Moderna by 364.5% during the 2nd quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock worth $79,163,000 after buying an additional 2,251,497 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Moderna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after buying an additional 1,420,690 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after acquiring an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Moderna by 20.7% in the second quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock valued at $195,917,000 after acquiring an additional 1,217,408 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on MRNA shares. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. Berenberg Bank set a $28.00 target price on Moderna in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. UBS Group restated a “buy” rating on shares of Moderna in a report on Friday, November 21st. Finally, Citigroup dropped their target price on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $29.21.

Moderna Stock Performance

Shares of MRNA opened at $29.46 on Friday. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $48.92. The business has a 50-day moving average of $26.04 and a 200 day moving average of $27.05. The firm has a market cap of $11.51 billion, a P/E ratio of -3.65 and a beta of 1.11.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company’s revenue was down 45.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 earnings per share. As a group, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.